Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect Milestone Pharmaceuticals to post earnings of ($0.19) per share for the quarter.
Milestone Pharmaceuticals Trading Up 0.4 %
MIST traded up $0.01 during trading on Wednesday, hitting $1.29. 528,885 shares of the company's stock were exchanged, compared to its average volume of 859,245. The stock has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.72. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $2.75. The firm has a market cap of $68.70 million, a P/E ratio of -1.59 and a beta of 0.86.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. TD Cowen lowered shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 1st. Cowen cut shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. TD Securities lowered shares of Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. Finally, HC Wainwright reissued a "buy" rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Friday, March 28th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $17.00.
View Our Latest Stock Analysis on MIST
Milestone Pharmaceuticals Company Profile
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Featured Articles
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
